Bell JC - Search Results

1

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC. Bourgeois-Daigneault MC, et al. Among authors: bell jc. Sci Transl Med. 2018 Jan 3;10(422):eaao1641. doi: 10.1126/scitranslmed.aao1641. Sci Transl Med. 2018. PMID: 29298865

2

In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase.

Duncan PI, Stojdl DF, Marius RM, Bell JC. Duncan PI, et al. Among authors: bell jc. Mol Cell Biol. 1997 Oct;17(10):5996-6001. doi: 10.1128/MCB.17.10.5996. Mol Cell Biol. 1997. PMID: 9315658 Free PMC article.

3

The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing.

Duncan PI, Stojdl DF, Marius RM, Scheit KH, Bell JC. Duncan PI, et al. Among authors: bell jc. Exp Cell Res. 1998 Jun 15;241(2):300-8. doi: 10.1006/excr.1998.4083. Exp Cell Res. 1998. PMID: 9637771

4

The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia.

Abraham N, Jaramillo ML, Duncan PI, Méthot N, Icely PL, Stojdl DF, Barber GN, Bell JC. Abraham N, et al. Among authors: bell jc. Exp Cell Res. 1998 Nov 1;244(2):394-404. doi: 10.1006/excr.1998.4201. Exp Cell Res. 1998. PMID: 9806790

5

SR protein kinases: the splice of life.

Stojdl DF, Bell JC. Stojdl DF, et al. Among authors: bell jc. Biochem Cell Biol. 1999;77(4):293-8. Biochem Cell Biol. 1999. PMID: 10546892 Review.

6

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Stojdl DF, et al. Among authors: bell jc. Nat Med. 2000 Jul;6(7):821-5. doi: 10.1038/77558. Nat Med. 2000. PMID: 10888934

7

The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC. Stojdl DF, et al. Among authors: bell jc. J Virol. 2000 Oct;74(20):9580-5. doi: 10.1128/jvi.74.20.9580-9585.2000. J Virol. 2000. PMID: 11000229 Free PMC article.

8

Oncolytic viruses: programmable tumour hunters.

Bell JC, Garson KA, Lichty BD, Stojdl DF. Bell JC, et al. Curr Gene Ther. 2002 May;2(2):243-54. doi: 10.2174/1566523024605582. Curr Gene Ther. 2002. PMID: 12109220 Review.

9

Getting oncolytic virus therapies off the ground.

Bell JC, Lichty B, Stojdl D. Bell JC, et al. Cancer Cell. 2003 Jul;4(1):7-11. doi: 10.1016/s1535-6108(03)00170-3. Cancer Cell. 2003. PMID: 12892708 Free article.

10

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. Stojdl DF, et al. Among authors: bell jc. Cancer Cell. 2003 Oct;4(4):263-75. doi: 10.1016/s1535-6108(03)00241-1. Cancer Cell. 2003. PMID: 14585354 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters